Table 2.
Clinical landscape of LAG-3-targeted therapy (https://clinicaltrials.gov/, accessed on 2 May 2021.)
| Phase | Therapy | NCT Identifier | Intervention/Treatment Tested | Condition or Disease |
|---|---|---|---|---|
| Early I | Monotherapy | NCT04566978 | Anti-LAG-3 (89Zr-DFO-REGN3767) | Large B-cell Lymphoma, DLBCL |
| I | Monotherapy | NCT03489369 | Anti-LAG-3 (Sym022) | Metastatic Cancer, Solid Tumor, Lymphoma |
| NCT03965533 | Anti-LAG-3 (GSK2831781) | Healthy Volunteers | ||
| NCT02195349 | Anti-LAG-3 (GSK2831781) | Psoriasis | ||
| NCT03538028 | Anti-LAG-3 (INCAGN02385) | Select Advanced Malignancies | ||
| NCT00351949 | LAG-3-Ig (Eftilagimod Alpha, IMP321) | Metastatic Renal Cell Carcinoma (MRCC) | ||
| Monotherapy and Combination | NCT03252938 | LAG-3-Ig (Eftilagimod alpha, IMP321), anti-PD-L1 (Avelumab), standard-of-care chemotherapy | Solid Tumors, Peritoneal Carcinomatosis | |
| NCT02658981 | Anti-LAG-3 (BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558), Anti-CD137 (Urelumab, BMS-663513) | Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm | ||
| NCT03250832 | Anti-LAG-3 (TSR-033), Anti-PD-1 | Advanced Solid tumors, Colorectal Cancer | ||
| NCT03005782 | Anti-LAG-3 (REGN3767), Anti-PD-1 (Cemiplimab, REGN2810) | Advanced Cancers | ||
| NCT02966548 | Anti-LAG-3 (Retalimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558) | Advanced Solid Tumors | ||
| NCT00354263 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Agrippal Reference Flu Antigen (commercially available flu vaccine) | Healthy Volunteers | ||
| Combination | NCT04658147 | Anti-LAG-3 (Relatlimab), Anti-PD-1 (Nivolumab) | Hepatocellular Carcinoma | |
| NCT03219268 | Anti-PD-1/Anti-LAG-3 DART protein MGD013, Anti-HER2 (Margetuximab, MGAH22) | Advanced Solid Tumors, Hematologic Neoplasms, Gastric Cancer, Ovarian Cancer, Gastroesophageal Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer | ||
| NCT03440437 | Anti-LAG-3/PD-L1 Bispecific Antibody (FS118) | Advanced Cancer, Metastatic Cancer | ||
| NCT00732082 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Gemcitabine (Gemzar) | Pancreatic Neoplasms | ||
| NCT03742349 | Anti-LAG-3 (LAG525, IMP701), Anti-PD-L1 (Spartalizumab, PDR001), Anti-A2AR (NIR178), MET inhibitor (capmatinib, INC280), Anti-M-CSF (MCS110), Anti-IL-1-beta (canakinumab, ACZ885) | Triple Negative Breast Cancer (TNBC) | ||
| NCT04140500 | Anti-PD1-LAG-3 Bispecific Antibody (RO7247669) | Solid Tumors | ||
| NCT03849469 | Anti-CTLA4-LAG-3 Bispecific Antibody (XmAb®22841), Anti-PD-1 (Pembrolizumab (Keytruda®)) | Selected Advanced Solid Tumors | ||
| NCT03311412 | Anti-LAG-3 (Sym022), Anti-TIM-3 (Sym023), Anti-PD-1 (Sym021) | Metastatic Cancer, Solid Tumors, Lymphoma | ||
| NCT02817633 | Anti-LAG-3 (TSR-033), Anti-PD-1 (TSR-042), Anti-TIM-3 (TSR-022) | Advanced or Metastatic Solid Tumors | ||
| NCT04252768 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Paclitaxel | Metastatic Breast Cancer | ||
| NCT02676869 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Anti-PD-1 (Pembrolizumab) | Unresectable or Metastatic Melanoma | ||
| NCT00349934 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Paclitaxel | Metastatic Breast Carcinoma | ||
| NCT00354861 | LAG-3-Ig (Eftilagimod Alpha, IMP321), hepatitis B antigen (without alum), Engerix B (hepatitis B antigen absorbed on alum) | Healthy Volunteers | ||
| NCT03493932 | Anti-LAG-3 (Relatimab, BMS-986016), Anti-PD-1 (Nivolumab) | Recurrent Glioblastoma Patients | ||
| NCT03044613 | Anti-LAG-3 (Relatlimab, BMS-986016) Anti-PD-1 (Nivolumab, Opdivo), Carboplatin, Paclitaxel, Radiation | Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer | ||
| NCT04641871 | Anti-LAG-3 (Sym022), Anti-TIM-3 (Sym023), Anti-PD-1 (Sym01) | Advanced Solid Tumor Malignancies | ||
| I/II | Monotherapy | NCT04618393 | Anti-PD-1-LAG-3 Bi-specific Antibody (EMB-02) | Advanced Solid Tumors |
| Monotherapy and Combination | NCT04706715 | Anti-LAG-3 (89Zr-DFO-REGN3767), Cemiplimab | Metastatic Solid Tumor | |
| NCT02460224 | Anti-LAG-3 (LAG525), Anti-PD1 (PDR001) | Advanced Solid Tumors | ||
| NCT01968109 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558), (BMS-986213) | Neoplasms by Site, Solid Tumors | ||
| Combination | NCT04611126 | Anti-LAG-3 (Relatlimab), Anti-PD-L1 (Ipilimumab), Anti-PD-1 (Nivolumab), Cyclophosphamid, Fludarabine Phosphate, Tumor Infiltrating Lymphocytes infusion | Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer | |
| NCT04150965 | Anti-LAG-3 (Relatlimab, BMS-986016), Elotuzumab (Empliciti), Pomalidomide, Dexamethasone, Anti-TIGIT (BMS-986207) | Multiple Myeloma, Relapsed Refractory Multiple Myeloma | ||
| NCT01308294 | LAG-3-Ig (ImmuFact-IMP321), Tumor Antigenic Peptides (NA-17, MAGE-3.A2, NY-ESO-1, Melan-A, MAGE-A3, MAGE-A3-DP4), Montanide ISA-51 | Melanoma | ||
| NCT00365937 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Immunological peptides and adjuvants, HLA-A2 peptides (Tyrosinase.A2, MAGE-C2.A2, MAGE-3.A2, MAGE-1.A2, NA17.A2 (GnTV), MAGE-10.A2), Montanide ISA51 | Melanoma | ||
| NCT03459222 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, Opdivo, BMS-936558), IDO1 Inhibitor (BMS-986205), Anti-CTLA-4 (Ipilimumab, Yervoy, BMS-734016) | Advanced Solid Cancers | ||
| NCT02488759 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab), Anti-CTLA4 (Ipilimumab), Anti-CD38 (Daratumumab, Darzalex) | Various Advanced Cancers | ||
| NCT02061761 | Anti-LAG-3 (BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558) | Hematologic Neoplasm (Refractory B-Cell Malignancies) | ||
| NCT03610711 | Anti-LAG-3 (Relatlimab), Anti-PD-1 (Nivolumab, Optivo) | Gastroesophageal Cancer | ||
| NCT04370704 | Anti-PD-1 (NCMGA00012), Anti-LAG-3 (INCAGN02385), Anti-TIM-3 (INCAGN02390) | Melanoma | ||
| II | Monotherapy | NCT03893565 | Anti-LAG-3 (GSK2831781) | Ulcerative Colitis |
| Monotherapy and Combination | NCT04080804 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD1 (Nivolumab, OPDIVO), Anti-CTLA4 (Ipilimumab, Yervoy) | Head and Neck Squamous Cell Carcinoma (HNSCC) | |
| NCT03743766 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD1 (Nivolumab, BMS-936558) | Melanoma | ||
| Combination | NCT04567615 | Anti-LAG-3 (Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD1 (Nivolumab, BMS-936558) | Advanced Hepatocellular Carcinoma | |
| NCT03484923 | Anti-LAG-3 IgG4 (LAG525), Anti-PD-1 (Spartalizumab, PDR001), Capmatinib (INC280), Canakinumab (ACZ885), Ribociclib (LEE011) | Melanoma | ||
| NCT04634825 | PD-1XLAG-3 bispecific DARTmolecule (Tebotelimab, MGD013), Anti-B7-H3 (Enoblituzumab, MGA271), Anti-PD-1 (Retifanlimab, INCMGA00012, MGA012) | Head and Neck Neoplasms | ||
| NCT04326257 | Anti-LAG-3 (Relatlimab), Anti-PD-1 (Nivolumab); Anti-PD-L1 (Ipilimumab) | Squamous Cell Carcinoma of the Head and Neck | ||
| NCT03625323 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Anti-PD-1 (Pembrolizumab, Keytruda, MK-3475) | Non-Small Cell Lung Carcinoma (NSCLC) and Head and Neck Carcinoma (HNSCC) | ||
| NCT03623854 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558) | Chordoma | ||
| NCT03662659 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, Opdivo, BMS-936558), (BMS-986213), XELOX (Oxaliplatin + capecitabine), FOLFOX (Oxaliplatin + leucovorin + fluorouracil), SOX (Oxaliplatin + tegafur/gimeracil/oteracil potassium) | Gastric or Gastroesophageal Junction (GEJ) Cancers | ||
| NCT02614833 | LAG-3-Ig (Eftilagimod Alpha, IMP321), Paclitaxel | Adenocarcinoma Breast Stage IV | ||
| NCT03365791 | Anti-LAG-3 (LAG525), Anti-PD-1 (PDR001) | Advanced Solid and Hematologic Malignancies | ||
| NCT02060188 | Anti-LAG-3 (BMS-986016), Anti-PD-1 (Nivolumab, Opdivo, BMS-936558) | Colorectal Cancer | ||
| NCT02519322 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, BMS-936558), surgery | Melanoma | ||
| NCT03642067 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, OPDIVO) | Advanced Colorectal Cancer | ||
| NCT03607890 | Anti-LAG-3 (Relatlimab, BMS-986016), Anti-PD-1 (Nivolumab, OPDIVO) | Advanced Mismatch Repair-Deficient Cancers | ||
| II/III | Combination | NCT04129320 | PD-1XLAG-3 bispecific DART protein (MGD013) Anti-B7-H3 (Enoblituzumab, MGA271), anti-PD-1 (MGA012, INCMGA00012) | Head and Neck Cancer |
| NCT04082364 | Anti-HER2 (margetuximab, MGAH22), Anti-PD-1/anti-LAG-3 dual checkpoint inhibitor DART molecule (MGD013), chemotherapy (XELOX (Capecitabine + Oxaliplatin), mFOLFOX-6 (Leucovorin + 5-FU + Oxaliplatin) | Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer |